Abstract
To develop an economic model to estimate the change in the number of events and costs of non-fatal myocardial infarction (MI) and non-fatal ischemic stroke (IS) as a result of implementing routine risk-stratification with a multiple inflammatory biomarker approach. Reductions in the numbers of non-fatal MI and non-fatal IS events and in related per-member-per-month (PMPM) and 5-year costs (excluding test costs) due to biomarker testing were modeled for a US health plan with one million beneficiaries. Inputs for the model included literature-based MI and IS incidence rates, healthcare costs associated with MI and IS, laboratory results of biomarker testing, MI and IS hazard ratios related to biomarker levels, patient monitoring and intervention costs and use/costs of preventative pharmacotherapy. Preventative pharmacotherapy inputs were based on an analysis of pharmacy claims data. Costs savings (2013 USD) were assessed for patients undergoing biomarker testing compared to the standard of care. Data from MDVIP and Cleveland Heart Lab supported two critical inputs: (1) treatment success rates and (2) the population distribution of biomarker testing. Incidence rates, hazard ratios, and other healthcare costs were obtained from the...Continue Reading
References
Nov 30, 2005·Archives of Internal Medicine·Christie M BallantyneEric Boerwinkle
Mar 28, 2006·The American Journal of Medicine·Brandi J WittVéronique L Roger
Jul 13, 2006·Archives of Internal Medicine·Aaron R FolsomA Richey Sharrett
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Dec 17, 2008·American Heart Journal·Amit SachdevaGregg C Fonarow
Mar 13, 2010·Journal of the American College of Cardiology·Claire L HeslopJohn S Hill
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Medicare Payment Advisory Commission U.S. Department Of Health And Human Services
May 19, 2011·PharmacoEconomics·Amy K O'SullivanDavid Thompson
Dec 15, 2012·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 2, 2013·Circulation·Elizabeth A MagnusonUNKNOWN FREEDOM Trial Investigators
Jul 10, 2013·Future Cardiology·Marc S Penn, Andrea B Klemes
Nov 14, 2013·Circulation·David C GoffGordon F Tomaselli
Mar 22, 2014·The New England Journal of Medicine·Michael J PencinaEric D Peterson